The effect of five day dosing with THCV on THC-induced cognitive, psychological and physiological effects in healthy male human volunteers: A placebo-controlled, double-blind, crossover pilot trial

Journal of Psychopharmacology

Volumn 30, Issue 2, 2016, Pages 140-151

  Englund, Amir ^a   Atakan, Zerrin ^a   Kralj, Aleksandra ^a   Tunstall, Nigel ^a   Murray, Robin ^a   Morrison, Paul ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

cannabinoid; cannabis; human; memory; psychosis; THC; THCV; 9 tetrahydrocannabinol; 9 tetrahydrocannabivarin

Indexed keywords

CANNABINOID; DELTA9 TETRAHYDROCANNABIVARIN; DRONABINOL; PLACEBO; UNCLASSIFIED DRUG; PSYCHEDELIC AGENT; TETRAHYDROCANNABIVARIN 9;

ADULT; ANXIETY; AROUSAL; ARTICLE; CANNABIS USE; COGNITION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEPRESSION; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; HEART RATE; HUMAN; HUMAN EXPERIMENT; MALE; MEMORY DISORDER; NEGATIVE SYNDROME; NORMAL HUMAN; PARANOIA; PILOT STUDY; PLEASURE; POSITIVE SYNDROME; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; SHORT TERM MEMORY; SYSTOLIC BLOOD PRESSURE; WORKING MEMORY; ANALOGS AND DERIVATIVES; DRUG EFFECTS; MEMORY; RECALL; YOUNG ADULT;

ADULT; COGNITION; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRONABINOL; HALLUCINOGENS; HEART RATE; HUMANS; MALE; MEMORY; MENTAL RECALL; PILOT PROJECTS; YOUNG ADULT;

EID: 84955479999     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881115615104     Document Type: Article

References (44)

1. Atakan Z, (2012) Cannabis, a complex plant: different compounds and different effects on individuals. Therapeut Adv Psychopharmacol 2: 241-254.
2. Beck AT, Epstein N, Brown G, et al. (1988) An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol 56: 893-897
3. Bergamaschi MM, Queiroz RHC, Chagas MHN, et al. (2014) Rimonabant effects on anxiety induced by simulated public speaking in healthy humans: a preliminary report. Human Psychopharmacol 29: 94-99.
4. Boggs DL, Kelly DL, McMahon RP, et al. (2012) Rimonabant for neurocognition in schizophrenia: a 16-week double blind randomized placebo controlled trial. Schizophrenia Res 134: 207-210.
5. 9-tetrahydrocannabinol in humans, with case histories. Psychopharmacology 219: 885-896.
6. Cascio MG, Zamberletti E, Marini P, et al. (2015) The phytocannabinoid, Δ 9-tetrahydrocannabivarin, can act through 5-HT 1A receptors to produce antipsychotic effects. Br J Pharmacology 172: 1305-1318.
7. Christensen R, Kristensen PK, Bartels EM, et al. (2007) Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet. 370: 1706-1713.
8. D'Souza DC, Perry E, MacDougall L, et al. (2004) The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology 29: 1558-1572.
9. D'Souza DC, Abi-Saab WM, Madonick S, et al. (2005) Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol Psychiatry 57: 594-608.
10. D'Souza DC, Ranganathan M, Braley G, et al. (2008) Blunted psychotomimetic and amnestic effects of delta-9-tetrahydrocannabinol in frequent users of cannabis. Neuropsychopharmacology 33: 2505-2516.
11. Dewey WL, (1986) Cannabinoid pharmacology. Pharmacologic Revs 38: 151-178.
12. Englund A, Stone JM, Morrison PD, (2012) Cannabis in the arm: what can we learn from intravenous cannabinoid studies? Current Pharmaceut Des 18: 4906-4914.
13. Englund A, Morrison PD, Nottage J, et al. (2013) Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment. J Psychopharmacol (Oxford) 27: 19-27.
14. Freeman D, Pugh K, Green C, et al. (2007) A measure of state persecutory ideation for experimental studies. J Nervous Mental Dis 195: 781-784.
15. Gill EW, Paton WD, Pertwee RG, (1970) Preliminary experiments on the chemistry and pharmacology of cannabis. Nature 228: 134-136.
16. Grotenhermen F, (2003) Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinetics 42: 327-360.
17. Hanus LO, (2009) Pharmacological and therapeutic secrets of plant and brain (endo)cannabinoids. Medicin Res Revs 29: 213-271.
18. Hillig KW, Mahlberg PG, (2004) A chemotaxonomic analysis of cannabinoid variation in Cannabis (Cannabaceae). Am J Botany 91: 966-975.
19. Hollister LE, (1974) Structure-activity relationships in man of cannabis constituents, and homologs and metabolites of delta9-tetrahydrocannabinol. Pharmacology 11: 3-11.
20. Horder J, Cowen PJ, Di Simplicio M, et al. (2009) Acute administration of the cannabinoid CB1 antagonist rimonabant impairs positive affective memory in healthy volunteers. Psychopharmacology 205: 85-91.
21. Horder J, Browning M, Di Simplicio M, et al. (2012) Effects of 7 days of treatment with the cannabinoid type 1 receptor antagonist, rimonabant, on emotional processing. J Psychopharmacol (Oxford) 26:, 125-132.
22. Lichtman AH, (2000) SR 141716A enhances spatial memory as assessed in a radial-arm maze task in rats. Euro J Pharmacol 404: 175-179.
23. Matthews G, Jones DM, Chamberlain AG, (1990) Refining the measurement of mood: The UWIST Mood Adjective Checklist. Br J Psychol 81: 17-42.
24. McPartland JM, Duncan M, Di Marzo V, et al. (2015) Are cannabidiol and Δ(9) -tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review. Br J Pharmacol 172: 737-753.
25. Mehmedic Z, Chandra S, Slade D, et al. (2010) Potency trends of Δ9-THC and other cannabinoids in confiscated cannabis preparations from 1993 to 2008. J Forensic Sci 55: 1209-1217.
26. Morgan CJA, Schafer G, Freeman TP, et al. (2010) Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study: naturalistic study [corrected]. Br J Psychiatry:J Mental Sci 197: 285-290.
27. Morrison PD, Stone JM, (2011) Synthetic delta-9-tetrahydrocannabinol elicits schizophrenia-like negative symptoms which are distinct from sedation. Human Psychopharmacol 26: 77-80.
28. Morrison PD, Zois V, McKeown DA, et al. (2009) The acute effects of synthetic intravenous Delta9-tetrahydrocannabinol on psychosis, mood and cognitive functioning. Psychol Med 39: 1607-1616.
29. Morrison PD, Nottage J, Stone JM, et al. (2011) Disruption of frontal θ coherence by Δ9-tetrahydrocannabinol is associated with positive psychotic symptoms. Neuropsychopharmacology 36: 827-836.
30. Naef M, Russmann S, Petersen-Felix S, et al. (2004) Development and pharmacokinetic characterization of pulmonal and intravenous delta-9-tetrahydrocannabinol (THC) in humans. J Pharmaceut Sci 93: 1176-1184.
31. Nissen SE, Nicholls SJ, Wolski K, et al. (2008) Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. JAMA 299: 1547-1560.
32. Pertwee RG, (2008) The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol 153: 199-215.
33. Pertwee RG, Thomas A, Stevenson LA, et al. (2007) The psychoactive plant cannabinoid, Delta9-tetrahydrocannabinol, is antagonized by Delta8- and Delta9-tetrahydrocannabivarin in mice in vivo. Br J Pharmacol 150: 586-594.
34. Potter DJ, (2014) A review of the cultivation and processing of cannabis (Cannabis sativa L.) for production of prescription medicines in the UK. Drug Test Anal 6: 31-38.
35. Rock EM, Sticht MA, Duncan M, et al. (2013) Evaluation of the potential of the phytocannabinoids, cannabidivarin (CBDV) and Δ(9) -tetrahydrocannabivarin (THCV), to produce CB1 receptor inverse agonism symptoms of nausea in rats. B J Pharmacol 170: 671-678.
36. Schubart CD, Sommer IEC, van Gastel WA, et al. (2011) Cannabis with high cannabidiol content is associated with fewer psychotic experiences. Schizophrenia Res 130: 216-221.
37. Shiflett MW, Rankin AZ, Tomaszycki ML, et al. (2004) Cannabinoid inhibition improves memory in food-storing birds, but with a cost. Proc R Soc Biol Sci 271: 2043-2048.
38. Stefanis NC, Hanssen M, Smirnis NK, et al. (2002) Evidence that three dimensions of psychosis have a distribution in the general population. Psychol Med 32: 347-358.
39. Stone JM, Morrison PD, Brugger S, et al. (2012) Communication breakdown: delta-9 tetrahydrocannabinol effects on pre-speech neural coherence. Mol Psychiatry 17: 568-569.
40. Terranova JP, Storme JJ, Lafon N, et al. (1996) Improvement of memory in rodents by the selective CB1 cannabinoid receptor antagonist, SR 141716. Psychopharmacology 126: 165-172.
41. Thomas A, Stevenson LA, Wease KN, et al. (2005) Evidence that the plant cannabinoid Delta9-tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist. Br J Pharmacol 146: 917-926.
42. Tudge L, Williams C, Cowen PJ, et al. (2014) Neural effects of cannabinoid CB1 neutral antagonist tetrahydrocannabivarin (THCv) on food reward and aversion in healthy volunteers. Int J Neuropsychopharmacol 18: ii.
43. Wargent ET, Zaibi MS, Silvestri C, et al. (2013) The cannabinoid Δ(9)-tetrahydrocannabivarin (THCV) ameliorates insulin sensitivity in two mouse models of obesity. Nutr Diabetes 3: e68.
44. Zuardi AW, Shirakawa I, Finkelfarb E, et al. (1982) Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacology 76: 245-250.